Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibCaroline Robert, Dirk Schadendorf, Florent Grange et al.|New England Journal of Medicine|2014Cited by 2.7k
3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanomaCaroline Robert, Dirk Schadendorf, Bogusława Karaszewska et al.|European Journal of Cancer|2015Cited by 80
Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous MelanomaCaroline Robert, Dirk Schadendorf, Bogusława Karaszewska et al.|Annals of Oncology|2014Cited by 7
3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)Jean‐Jacques Grob, Caroline Robert, Mayur M. Amonkar et al.|European Journal of Cancer|2015Cited by 0